Search

Sirolimus

[A242412] In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. … [A1320] Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants.

Procaine

(From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Procaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients [L1215].

VB10.16

It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting

Chlorambucil

(Merck Index, 11th ed)

Sodium phosphate, monobasic, unspecified form

Osimertinib

[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved

Gilteritinib

[A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018.

Rivastigmine

Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

Interleukin-7

Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.

Sotorasib

[A187547] Sotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 6, 2022.[L56070]